A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Summary

The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer (NSCLC).

Timeline

Start

2015-09-04

Primary completion

2017-01-26

Completion

2019-09-17

Outcome

Missed primary endpoint

registry analysis (other test); Part A Cohort 1: 600 mg Neci + 200 mg Pembro vs Part A Cohort 2, Part B: 800 mg Neci + 200 mg Pembro; p = 0.4491; Fisher Exact NCT02451930 ↗

Drugs

Indications